Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine versus entecavir in CKD patients with chronic hepatitis B receiving long-term immunosuppressive therapy
ChiCTR-TRC-13004454Phase 4Recruiting
- Sponsor
- First Affiliated Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by First Affiliated Hospital. Primary endpoints: Vital signs, 24-hour urinary protein and 29 more. Started Jan 2014; status: recruiting.
02
Drugs
telbivudineentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-TRC-13004454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004454.